PR
ProQR Therapeutics N.V.
PRQR · NASDAQ
$1.83 -3.17% (-$0.06)
1M -24.69%
Market Cap 167.8M €
P/E Ratio -
Div. Yield -
ROE 68.44%
Piotroski F-Score Weak
1/9Valuation
43 /100
Fair P/B 2.11x
P/S 9.04x
EV/EBITDA N/A
Growth
78 /100
Growing Book val. growth 9.72%
Rev. growth 61.99%
FCF growth N/A
Profitability
20 /100
Weak Net margin 228.29%
Op. margin 232.71%
FCF margin 270.78%
Quality
2 /100
Poor ROE 68.44%
ROA 31.76%
Asset turnover 0.14x
Debt
100 /100
Low Current ratio 3.49x
Debt/Equity 0.17x
Net debt/EBITDA N/A
Stability
16 /100
Unstable Rev. volatility 104.73%
EPS volatility 38.80%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre PRQR
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Daniel Anton de Boer
Employees
166
Headquarters
Leiden
Evenimente viitoare
05 NOV.
Earnings
Upcoming earnings report